Ignite Creation Date:
2024-05-05 @ 11:40 PM
Last Modification Date:
2024-10-26 @ 10:37 AM
Study NCT ID:
NCT01382368
Status:
UNKNOWN
Last Update Posted:
2012-11-15
First Post:
2011-05-02
Brief Title:
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD IPF and Post Pneumonectomy Patients
Sponsor:
Rabin Medical Center
Organization:
Rabin Medical Center
Study Overview
Official Title:
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD IPF and Post Pneumonectomy Patients
Status:
UNKNOWN
Status Verified Date:
2012-11
Last Known Status:
ENROLLING_BY_INVITATION
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pulmonary diseases are increasingly important causes of morbidity and mortality in the modern world
Sildenafil an orally administered a phosphodiesterase type 5 PDE-5 inhibitor targets the nitric oxide NO pathway The drug was first approved for the treatment of Pulmonary Arterial Hypertension PAH in 2005
The aim of the suggested study is to examine the acute effect of oral intake of sildenafil on exercise tolerance and functional capacity in Chronic Obstructive Pulmonary Disease COPD Idiopathic pulmonary fibrosis IPF and post Pneumonectomy patients
The investigators hypothesize that oral ingestion of sildenafil prior the exercise may enhance exercise tolerance and improve function in COPD IPF and post Pneumonectomy patients
Patients and Methods
Sixty chronic lung disease patients males and females aged 30 to 90 years 20 COPD GOLD III-IV 9 39 20 IPF and 20 post Pneumonectomy patients will be recruit to this study
All subjects will carried out two maximal cardiopulmonary exercise tests CPET on bicycle ergometer in different days 60 min after intake of placebo and 60 min after intake of 100 mg sildenafil Pfizer Sandwich UK in random order
In first meeting prior exercise test at rest standard pulmonary function test diffusion of CO TLC and RV will be measured In addition Doppler Echocardiography and blood samples for NT-proBNP will be taken prior and post each CPET
After 15-20 minute of passive recovery post exercise test all patients will perform 3 short functional tests including 6 minute walk test to assess functional capacity
Sildenafil an orally administered a phosphodiesterase type 5 PDE-5 inhibitor targets the nitric oxide NO pathway The drug was first approved for the treatment of Pulmonary Arterial Hypertension PAH in 2005
The aim of the suggested study is to examine the acute effect of oral intake of sildenafil on exercise tolerance and functional capacity in Chronic Obstructive Pulmonary Disease COPD Idiopathic pulmonary fibrosis IPF and post Pneumonectomy patients
The investigators hypothesize that oral ingestion of sildenafil prior the exercise may enhance exercise tolerance and improve function in COPD IPF and post Pneumonectomy patients
Patients and Methods
Sixty chronic lung disease patients males and females aged 30 to 90 years 20 COPD GOLD III-IV 9 39 20 IPF and 20 post Pneumonectomy patients will be recruit to this study
All subjects will carried out two maximal cardiopulmonary exercise tests CPET on bicycle ergometer in different days 60 min after intake of placebo and 60 min after intake of 100 mg sildenafil Pfizer Sandwich UK in random order
In first meeting prior exercise test at rest standard pulmonary function test diffusion of CO TLC and RV will be measured In addition Doppler Echocardiography and blood samples for NT-proBNP will be taken prior and post each CPET
After 15-20 minute of passive recovery post exercise test all patients will perform 3 short functional tests including 6 minute walk test to assess functional capacity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None